The estimated Net Worth of Charles L Cooney is at least $499 dollars as of 16 February 2023. Charles Cooney owns over 8,750 units of Codiak BioSciences stock worth over $499 and over the last 4 years Charles sold CDAK stock worth over $0.
Charles has made over 1 trades of the Codiak BioSciences stock since 2023, according to the Form 4 filled with the SEC. Most recently Charles exercised 8,750 units of CDAK stock worth $499 on 16 February 2023.
The largest trade Charles's ever made was exercising 8,750 units of Codiak BioSciences stock on 16 February 2023 worth over $499. On average, Charles trades about 1,750 units every 0 days since 2020. As of 16 February 2023 Charles still owns at least 8,750 units of Codiak BioSciences stock.
You can see the complete history of Charles Cooney stock trades at the bottom of the page.
Charles's mailing address filed with the SEC is C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE, MA, 02140.
Over the last 4 years, insiders at Codiak BioSciences have traded over $15,220 worth of Codiak BioSciences stock and bought 11,821,475 units worth $20,798,957 . The most active insiders traders include Steven Gillis, Venture Fund Viii, L.P.Arch... et Permanent Fund Corp Alaska. On average, Codiak BioSciences executives and independent directors trade stock every 25 days with the average trade being worth of $19,158. The most recent stock trade was executed by Yalonda Howze on 30 March 2023, trading 1,628 units of CDAK stock currently worth $326.
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Codiak BioSciences executives and other stock owners filed with the SEC include: